Manages OA. 1.2 Rheumatoid Arthritis (RA). Sold as Celebrex, Vyscoxa, Elyxyb. Every FDA application for this active ingredient: 4 branded and 26 generic.
As of Nov 15, 2026, FDA lists 30 applications for Celecoxib (sold as Celebrex, Vyscoxa, Elyxyb), first approved Dec 31, 1998, with 6 new uses approved and 0 published complete response letters.
| Celecoxib | Part D | $149M | -10% | 2,142,195 |
| Celebrex | Part D | $11.4M | -17% | 2,827 |
| Elyxyb | Part D | $1.9M | +11% | 396 |
| Vyscoxa | Part D | $0K | New | 0 |
| Physical Therapy for the Management of Postoperative Pain After Minimally Invasive Thoracic SurgeryPost Operative Pain · University of Miami | Phase 4 | Not yet recruiting | Nov 12, 2026 |
| Ivarmacitinib With or Without Celecoxib for Ankylosing SpondylitisAnkylosing Spondylitis (AS) · Peking University Third Hospital | Phase 4 | Not yet recruiting | Oct 26, 2026 |
| Preoperative Celecoxib and Acetaminophen Versus Acetaminophen Alone for Pain Control After Pediatric AdenotonsillectomyAdenotonsillectomy, Postoperative Pain · NYU Langone Health | Phase 1 / Phase 2 | Not yet recruiting | Oct 13, 2026 |
| Long-term Follow-up of Bio-signals and Quality of Recovery Following Implementation of ERAS Based on the Mobile ApplicationGynecologic Surgery, General Anesthesia · Wonju Severance Christian Hospital | Not applicable | Enrolling by invitation | Oct 9, 2026 |
| Pain After Scheduled Cesarean Delivery: Spinal Morphine With or Without Levobupivacaine Wound InfiltrationPain Management, C Section · Fundación Santa Fe de Bogota | — | Not yet recruiting | Oct 6, 2026 |
| Study on the Effect of Electronic Moxibustion on Non-Specific Low Back Pain in Young AdultsElectronic Moxibustion, Low Back Pain · Nanfang Hospital, Southern Medical University | Not applicable | Not yet recruiting | Oct 5, 2026 |
| Electroconvulsive Therapy for Refractory FibromyalgiaFibromyalgia (FM) · Beijing Tiantan Hospital | Not applicable | Not yet recruiting | Sep 23, 2026 |
| The Impact of Regional Motor-sparing Blocks on Early Rehabilitation Following Primary Hip or Knee ArthroplastyTotal Hip Arthroplasty (THA) or Total Knee Arthroplasty (TKA), Preoperative Adductor Canal Block (ACB) · Poznan University of Physical Education | Not applicable | Not yet recruiting | Sep 22, 2026 |
| Dec 31, 1998 | CelebrexNDA 20998 · New molecular entity | Upjohn | 30 | Marketed |
| Dec 23, 1999 | CelebrexNDA 21156 · TYPE 6 | Gd Searle LLC | 3 | Marketed |
| May 30, 2014 | CelecoxibANDA 76898 | Teva | 1 | Marketed |
| Feb 11, 2015 | CelecoxibANDA 78857 | Pharmazone | 5 | Discontinued |
| Feb 11, 2015 | CelecoxibANDA 200562 | Watson Labs Inc | 6 | Marketed |
| Jun 2, 2015 | CelecoxibANDA 204197 | Apotex | 6 | Marketed |
| Jun 9, 2015 | CelecoxibANDA 202240 | Lupin | 6 | Marketed |
| Aug 21, 2015 | CelecoxibANDA 204519 | Alembic | 5 | Marketed |
| Sep 23, 2015 | CelecoxibANDA 207446 | Cipla | 5 | Marketed |
| Dec 23, 2015 | CelecoxibANDA 207677 | Torrent | 5 | Marketed |
| Feb 1, 2016 | CelecoxibANDA 206827 | Aurobindo Pharma | 5 | Marketed |
| Mar 16, 2016 | CelecoxibANDA 204590 | Macleods Pharms | 8 | Marketed |
| Apr 4, 2017 | CelecoxibANDA 207061 | Jubilant Generics | 1 | Discontinued |
| Jan 23, 2018 | CelecoxibANDA 210071 | Cspc Ouyi | 4 | Marketed |
| Apr 30, 2018 | CelecoxibANDA 204776 | Micro Labs | 5 | Marketed |
| May 31, 2018 | CelecoxibANDA 208833 | Amneal Pharms | 4 | Discontinued |
| Aug 7, 2019 | CelecoxibANDA 208856 | Qingdao Baheal Pharm | 1 | Marketed |
| Nov 14, 2019 | CelecoxibANDA 208701 | Cadila Pharms Ltd | 2 | Marketed |
| Nov 27, 2019 | CelecoxibANDA 210628 | Pharmazone | 2 | Marketed |
| Feb 25, 2020 | CelecoxibANDA 207872 | Tianjin Tianyao | 1 | Marketed |
| Mar 6, 2020 | CelecoxibANDA 211412 | Pharmobedient | 2 | Marketed |
| May 5, 2020 | ElyxybNDA 212157 · New dosage form | Scilex Pharms | 2 | Marketed |
| May 13, 2020 | CelecoxibANDA 213598 | Nanjing | 3 | Marketed |
| Dec 3, 2020 | CelecoxibANDA 205129 | Sciegen Pharms | 3 | Marketed |
| Dec 9, 2020 | CelecoxibANDA 212925 | Pangea | 0 | Discontinued |
| Jan 12, 2021 | CelecoxibANDA 213301 | Unichem | 2 | Discontinued |
| Apr 10, 2023 | CelecoxibANDA 212564 | Yabao Pharm | 0 | Discontinued |
| Apr 29, 2025 | CelecoxibANDA 213127 | Strides Pharma | 0 | Discontinued |
| Jul 14, 2025 | CelecoxibANDA 205938 | Zydus Pharms | 0 | Discontinued |
| Jul 29, 2025 | VyscoxaNDA 211759 · New dosage form | Carwin Pharm Assoc | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA